CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
CDT Equity (NASDAQ:CDT) has announced its Board's approval of a cryptocurrency-based treasury reserve strategy to diversify its balance sheet management approach. The company will partner with Sarborg to develop an AI-led system for cryptocurrency market evaluation, featuring real-time analytics and automated execution systems.
The decision follows a strategic review of the cryptocurrency and stablecoin market, including consultations with third-party experts and stakeholders. CDT currently has 3,382,025 shares of common stock outstanding, with 250,000,000 authorized shares. The company continues to fund operations through its ATM facility with A.G.P./Alliance Global Partners while maintaining focus on its Phase-2 ready pharmaceutical pipeline.
CDT Equity (NASDAQ:CDT) ha annunciato che il proprio consiglio di amministrazione ha approvato una strategia di riserva patrimoniale basata sulle criptovalute per diversificare la gestione del bilancio. La società collaborerà con Sarborg per sviluppare un sistema guidato dall'IA per la valutazione del mercato delle criptovalute, con analisi in tempo reale e sistemi di esecuzione automatizzati.
La decisione segue una revisione strategica del mercato delle criptovalute e degli stablecoin, inclusi confronti con consulenti esterni e stakeholder. Attualmente CDT ha 3.382.025 azioni ordinarie in circolazione, con 250.000.000 azioni autorizzate. La società continua a finanziare le operazioni tramite la sua struttura ATM con A.G.P./Alliance Global Partners, mantenendo al contempo l'attenzione sul suo portafoglio farmaceutico pronto per la Fase 2.
CDT Equity (NASDAQ:CDT) ha anunciado que su junta directiva aprobó una estrategia de reserva de tesorería basada en criptomonedas para diversificar la gestión del balance. La compañía se asociará con Sarborg para desarrollar un sistema liderado por IA para la evaluación del mercado de criptomonedas, con análisis en tiempo real y sistemas de ejecución automatizados.
La decisión se produce tras una revisión estratégica del mercado de criptomonedas y stablecoins, que incluyó consultas con expertos externos y partes interesadas. CDT dispone actualmente de 3.382.025 acciones ordinarias en circulación, con 250.000.000 acciones autorizadas. La empresa sigue financiando sus operaciones mediante su mecanismo ATM con A.G.P./Alliance Global Partners, manteniendo a la vez el enfoque en su cartera farmacéutica lista para la Fase 2.
CDT Equity (NASDAQ:CDT)는 재무제표 관리를 다각화하기 위한 암호화폐 기반 재무준비금 전략을 이사회에서 승인했다고 발표했습니다. 회사는 암호화폐 시장 평가를 위해 실시간 분석과 자동 실행 시스템을 갖춘 AI 주도 시스템을 개발하기 위해 Sarborg와 협력할 예정입니다.
이번 결정은 제3자 전문가 및 이해관계자와의 협의를 포함한 암호화폐 및 스테이블코인 시장에 대한 전략적 검토에 따른 것입니다. 현재 CDT는 3,382,025주의 보통주가 발행되어 있으며, 250,000,000주의 승인 주식 수를 보유하고 있습니다. 회사는 A.G.P./Alliance Global Partners와의 ATM(At-the-Market) 시설을 통해 운영 자금을 계속 조달하면서도 2상 준비가 된 제약 파이프라인에 집중하고 있습니다.
CDT Equity (NASDAQ:CDT) a annoncé que son conseil d'administration a approuvé une stratégie de réserve de trésorerie basée sur les cryptomonnaies afin de diversifier la gestion de son bilan. La société s'associera à Sarborg pour développer un système piloté par l'IA pour l'évaluation du marché des cryptomonnaies, incluant des analyses en temps réel et des systèmes d'exécution automatisés.
La décision fait suite à une revue stratégique du marché des cryptomonnaies et des stablecoins, incluant des consultations avec des experts tiers et des parties prenantes. CDT détient actuellement 3 382 025 actions ordinaires en circulation, avec 250 000 000 actions autorisées. La société continue de financer ses opérations via sa facilité ATM avec A.G.P./Alliance Global Partners, tout en restant concentrée sur son pipeline pharmaceutique prêt pour la Phase 2.
CDT Equity (NASDAQ:CDT) hat bekannt gegeben, dass der Vorstand eine kryptowährungsbasierte Treasury-Reserve-Strategie zur Diversifizierung der Bilanzverwaltung genehmigt hat. Das Unternehmen wird mit Sarborg zusammenarbeiten, um ein KI-gestütztes System zur Bewertung des Kryptowährungsmarktes zu entwickeln, das Echtzeitanalysen und automatisierte Ausführungssysteme bietet.
Die Entscheidung folgt auf eine strategische Überprüfung des Kryptomarkt- und Stablecoin-Umfelds, einschließlich Beratungen mit externen Experten und Stakeholdern. CDT hat derzeit 3.382.025 ausstehende Stammaktien und 250.000.000 genehmigte Aktien. Das Unternehmen finanziert seine Geschäftstätigkeit weiterhin über seine ATM-Fazilität mit A.G.P./Alliance Global Partners und konzentriert sich zugleich auf seine für Phase 2 bereite Pharma-Pipeline.
- Strategic diversification of capital structure through cryptocurrency exposure
- Development of AI-led cryptocurrency evaluation system with automated execution
- Simple capital structure positions company for potential transformative transactions
- Maintains strong pharmaceutical pipeline with Phase-2 ready assets
- Significant exposure to volatile cryptocurrency market risks
- Continued reliance on ATM facility for primary funding
- Potential Nasdaq delisting risk mentioned in forward-looking statements
- Complex regulatory environment for both crypto and pharmaceutical operations
Insights
CDT's move into crypto treasury reserves represents a significant strategic shift for a pharmaceutical company with unclear risk/reward profile.
CDT Equity's decision to adopt a cryptocurrency treasury reserve strategy marks a substantial departure from traditional pharmaceutical company capital management approaches. The company plans to diversify its balance sheet by holding digital assets, positioning itself for what it describes as both strategic and financial benefits. This move comes amid what CDT characterizes as significant market activity in the cryptocurrency sector.
The company is partnering with Sarborg to develop an AI-led system for cryptocurrency market evaluation, including real-time analytics and automated execution systems. This suggests CDT is attempting to implement sophisticated infrastructure rather than making ad-hoc crypto investments.
What's particularly notable is the stark contrast between CDT's core business and this new treasury strategy. The company describes itself as focused on Phase-2 ready pharmaceutical assets built on algorithmic repurposing and solid-form drug development - activities with no inherent connection to cryptocurrency markets.
The announcement reveals CDT has a simple capital structure with only 3.38 million outstanding shares (against 250 million authorized), and relies primarily on an at-the-market facility for funding. This substantial authorized-but-unissued share capacity suggests potential for significant dilution if the company pursues this strategy aggressively.
This represents a high-risk strategic pivot that introduces substantial volatility and regulatory uncertainty to what would traditionally be conservative treasury management. While potentially appealing to crypto-enthusiastic investors, it adds layers of complexity and risk unrelated to CDT's pharmaceutical development business, creating a hybrid investment profile that may confuse the market about the company's core value proposition.
Cryptocurrency treasury reserve strategy is designed to diversify capital structure while reinforcing CDT's innovation-led model
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today announced that, following its strategic review of the cryptocurrency and stablecoin market, engagement with third-party consultants and conversations with stakeholders, the Board has approved a cryptocurrency-based treasury reserve strategy to hold part of its current balance sheet, diversifying its capital management approach for the Company's assets.
The decision reflects the Company's conviction that long-term exposure to digital assets presents both strategic and financial benefits for investors. The Board recognizes the significant market activity from investors and sponsors in the cryptocurrency and stablecoin sector and believes it could be positioned to execute a potentially transformative transaction given its simple capital structure.
In parallel, CDT is working with Sarborg to develop an autonomous multi-agent AI-led system to evaluate the cryptocurrency market, enabling real-time analytics, automated execution systems, and a structured rebalancing framework that mirrors best practices in digital asset markets. Meanwhile, the Company remains focused on progressing its pipeline of Phase-2 ready pharmaceutical assets, which is built upon a foundation of algorithmic repurposing, integration, solid-form drug development, and IP-led licensing opportunities.
As of September 2, 2025, the total number of shares of common stock outstanding was 3,382,025 and the total authorized shares of common stock are 250,000,000 shares. CDT continues to utilize its at-the-market (ATM) facility with A.G.P./Alliance Global Partners as its primary source of funding.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; its ability to effectively implement a cryptocurrency treasury reserve strategy; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors & Media:
info@cdtequity.com
FAQ
What is CDT Equity's new cryptocurrency treasury reserve strategy?
How many shares of CDT stock are currently outstanding?
How is CDT Equity (NASDAQ:CDT) funding its operations?
What is the current status of CDT's pharmaceutical pipeline?
What are the main risks associated with CDT's new crypto strategy?
